February 11, 2026 4:45pm

Good econ release stimulates bad news as Ai sell-off continues with the C&GT sector settling with a daily deeper bottom

It’s good to be right, yet again after other agains …

Moderna (MRNA -$1.49 or -3.54% to $40.51) shares fell after FDA wouldn’t review their application for experimental flu shot. MRNA said the move is inconsistent with previous feedback the FDA gave before it submitted the application and started phase 3 trials on the shot, called mRNA-1010, and that the FDA did not identify any specific safety or efficacy issues with the vaccine.

RMi collects, curates, interprets and disseminates cell and gene therapy sector (C&GT) fact-based news, trustable and verified intel of share pricing data bridging the gap to an investment decision

Never leave a retail investor uninformed!  It’s not always time to buy or sell; but it is time to KNOW why!

I write this blog/newsletter to inform investors with facts and supporting numbers focused on what they need to hear that others will not say or write about – facts in evidence!  I’m NOT at all writing a doom-and-gloom predictions as I am more frequently right than consequentially wrong; I am mostly EARLY in my prognostications!

RMi Pre-opening: Wobbling … https://www.regmedinvestors.com/articles/14308

 

I chose to speak-up when many analysts, brokers and commentators have shut-up!

 

Wednesday: The Dow closed DOWN -66.74 points or -0.13%, the S&P closed DOWN -0.34 points or -0.00% while the Nasdaq closed DOWN -36.007 points or -0.16%

  • Theme of the session: momentum wains with exaggerated pain

Wednesday’s (my) 40-company covered sector’s advance/decline line opened negative with 12 incliners, 26 decliners and 2 flats, ending with a negative close of 12 incliners, 25 decliners and 3 flats

  • The day’s DOWNSIDE moves come after the broad-based S&P 500 suffered losses Tuesday as worries over AI’s impact on the financial sector weighed on the index.

Henry’omics: We need to more than consider the macro-economic environment to comprehend the cause and effect of the macro versus micro data affecting “our” universe of cell and gene therapy (C&GT) sector

  • The Bureau of Labor Statistics’ January nonfarm payrolls report which had been delayed due to a partial government shutdown that ended on 2/3 showed job growth of 130,000 last month. Economists had called for a gain of 55,000. The latest figure also marked a sizable increase from December, which was downwardly revised to 48,000. The unemployment rate also landed at 4.3%, a bit below the Dow Jones forecast for 4.4%.

The CBOE Fear (VIX) index, Wednesday closed at 17.71, after Tuesday’s 17.23, Monday’s 17.44, Friday’s 17.75, Thursday’s 21.63 and last Wednesday’s 19.25

Metrics: Tuesday …

  • The RUT was down -10.30 points or -0.38%,
  • The XLV was up +0.92 points or +0.59%,
  • The NBI was up+26.75 points or +0.44%;
  • The XBI was down -0.69 points or -0.55%
  • The IWM was down -1.20 or -0.45%;
  • The IBB was up +0.64 points or +0.37%,
  • The VIX was down -0.08 points or -0.45% at to 17.71

 

Q1/26 February – 5 negative and 3 positive sessions

  • January – 2 holidays, 2 neutral, 9 negative and 9 positive closes

Q4/25 …

  • December – 1 holiday, 8 positive and 14 negative closes
  • November – 1 holiday, 8 positive and 11 negative closes
  • October -1 neutral, 11 positive and 12 negative closes

 

Wednesday Closing UP (12 of 12) 

  • BioNTech (BNTX +$0.45 after Tuesday’s -$1.41 after Monday’s +$3.72),
  • Mesoblast (MESO +$0.31 after Tuesday’s +$1.21 after Monday’s +$0.83),
  • Entrada Therapeutics (TRDA +$0.25 after Tuesday’s +$0.28),
  • Precigen (PGEN +$0.25 after Tuesday’s +$0.10),
  • Supernus Therapeutics (SUPN +$0.13),
  • Fate Therapeutics (FATE +$0.10),
  • Ionis Pharmaceuticals (IONS -$0.06 after Tuesday’s -$0.50 after Monday’s -$1.71),
  • MiMedx (MDXG +$0.04),
  • Prime Medicine (PRME +$0.03),
  • Caribou Biosciences (CEBU +$0.02),
  • Sangamo Therapeutics (SGMO +$0.0013)

Flat (3)

  • Generation Bio (GBIO) – acquired
  • Harvard Apparatus RT (OTCQB: HRGN $0.00 after Tuesday’s +$0.10 <with 660 shares> after Monday’s $0.00),
  • Rocket Therapeutics (RCKT)

Wednesday’s Closing DOWN (10 of 25): 

  • IQIA Holdings (IQV -$5.29 after Tuesday’s -$10.22 after Monday’s +$5.27),
  • Vertex (VRTX -$2.24 after Tuesday’s -$7.39 after Monday’s -$7.05),
  • Moderna (MRNA -$1.49),
  • Arrowhead Pharmaceuticals (ARWR -$1.37 after Tuesday’s +$0.32 after Monday’s -$1.88),
  • Alnylam Pharmaceuticals (ALNY -$1.23 after Tuesday’s +$2.98 after Monday’s -$8.16),
  • Beam Therapeutics (BEAM -$0.96),
  • Vericel (VCEL -$0.96 after Tuesday’s +$0.15 after Monday’s -$0.75),
  • AxoGen (AXGN -$0.61 after Tuesday’s +$0.58 after Monday’s -$1.00),
  • uniQure NV (QURE -$0.60 after Tuesday’s -$1.34 after Monday’s +$0.40),
  • Solid Biosciences (SLDB -$0.53),

 

The Bottom Line: More of the … WHY

C&GT sector bleeds share pricing again

Indexes were downsized on Wednesday, as investors ingested a January jobs report that blew past expectations on a monthly basis.

  • The report signaled a resilience in the labor market despite showing a heavily revised picture for last year, but it also bolstered the case for interest rates to stay on hold for the foreseeable future.
  • The unemployment rate ticked down slightly to 4.3% from 4.4%.

 

Thursday’s Q4 and FY25 sector earnings releases should/could provide further insight into cell and gene therapy sector investor “feelings”

Earnings release dates:

  • 2/12 – Alnylam Pharmaceuticals (ALNY), Vertex (VRTX) and Ultragenyx Pharmaceuticals (RARE)
  • 2/13 – Moderna (MRNA)
  • Tuesday - 2/24 – AxoGen (AXGN)
  • Wednesday – 2/25 – Ionis Pharmaceuticals (IONS) and Sarepta Theoretics (SRPT)

 

RISK is always a factor remaining below the surface …  boiled-up as slight shocks of profiteering on upsides shook but not rocked the C&GT sector and markets!

  • As I had also written, cash is king for investors who want to keep some liquidity and avoid having to sell in a down market,

 

February – 2nd week

  • 2/11 - Wednesday closed negative with 12 incliners, 25 decliners and 3 flats
  • 2/10 - Tuesday closed negative with 19 incliners, 20 decliners and 1 flat
  • 2/9 - Monday closed positive with 23 incliners, 14 decliners and 3 flats

February – 1st week

  • 2/6 – Friday closed positive with 35 incliners, 5 decliners and 0 flat
  • 2/5 -Thursday closed negative with 2 incliners, 36 decliners and 2 flats
  • 2/4 -Wednesday closed negative with 10 incliners, 29 decliners and 1 flat               
  • 2/3 -Tuesday closed negative with 18 incliners, 21 decliners and 1 flat      
  • 2/2 -Monday closed positive with 29 incliners, 10 decliners and 1 flat

 

As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!

 

Why do I keep repeating, framed in a different para, so investors can make the connection

The top three (3) performing in the session:    Winners

  • Wednesday: BioNTech (BNTX), Mesoblast (MESO) and Entrada Therapeutics (TRDA)
  • Tuesday: Alnylam Pharmaceuticals (ALNY), Mesoblast (MESO) and AxoGen (AXGN)
  • Monday: IQIA Holdings (IQV), BioNTech (BNTX) and Mesoblast (MESO)
  • Friday: Vertex (VRTX), IQIA Holdings (IQV) and Ionis Pharmaceuticals (IONS)

The worst three (3) in the session: Losers

  • Wednesday: IQIA Holdings (IQV), Vertex (VRTX) and Moderna (MRNA) 
  • Tuesday: IQIA Holdings (IQV), Vertex (VRTX) and Regenxbio (RGNX)
  • Monday: BioNTech (BNTX), Alnylam Pharmaceuticals (ALNY) and Arrowhead Pharmaceuticals (ARWR)
  • Friday: Alnylam Pharmaceuticals (ALNY), Moderna (MRNA) and Generation Bio (GBIO)

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.